Key Takeaways A one-year Parkinson’s stem cell trial called STEM-PD found no serious side effects linked to the cell product itself. Scientists used embryonic stem cells to grow dopamine producing cells, then transplanted them into eight patients with Parkinson’s disease. Six of seven surviving patients cut their Parkinson’s medication substantially,
Key Takeaways A new randomized trial tested injecting mesenchymal stem cells into the spinal fluid of 18 people with progressive MS. The trial’s main measure of nerve repair did not improve. The result was not statistically significant. Some secondary signals looked promising at six months but faded by twelve months.
Key Takeaways A new human trial injected lab-grown heart muscle cells into 20 patients with advanced heart failure during bypass surgery. Patients who received the cells walked further, showed better heart blood flow, and had thicker heart muscle than those who had surgery alone. Pumping strength, scar size, and quality
Key Takeaways A new umbilical cord exosome study, published in Stem Cell Research & Therapy, tested umbilical cord mesenchymal stem cell-derived vesicles in patients with sudden hearing loss that had not responded to steroids. Researchers set out to evaluate the safety of injecting these vesicles through the eardrum. They found
Key Takeaways A 2026 study in Scientific Reports followed 49 patients with steroid-resistant GvHD treated with Wharton’s jelly MSCs at four hospitals in Spain. At day 28, 71.4% of patients responded to treatment. One-year survival reached 55.1%. Batches that scored above 70% on a potency test produced far better outcomes,
